NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00124709,Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification,https://clinicaltrials.gov/study/NCT00124709,,TERMINATED,"This study consists of a 3-year double-blind phase during which patients will receive atopic dermatitis (AD) treatment either with pimecrolimus cream 1% long-term management (LTM) or with a conventional corticosteroid-based treatment (1:1 ratio), followed by a 2 to 3-year open-label (OL) phase (all patients receiving pimecrolimus cream 1% LTM). At the end of the double-blind phase, the two treatment groups will be compared with respect to their efficacy in controlling AD; at the end of the OL phase, the incidence of asthma at the age of 6 years will be compared.",YES,Atopic Dermatitis,DRUG: Pimecrolimus|DRUG: Corticosteroid,"Atopic Dermatitis (AD) Disease Control Over 36 Months, Proportion of disease-free days in Step 2 or less (per Patient) using total number of days in study as the denominator- double-blind phase. Intent to Treat Population: defined as all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement., 36 months|Effect of Early Use of Pimecrolimus Cream 1% in Reducing the Incidence of Asthma at 6 Years of Age, Note: The results for this efficacy variable are not reported due to early termination of the study., 6 years","Long Term Safety in Infants and Young Children, Note: The results of this secondary outcome is not reported due to early termination of the study., 6 years|Incidence of Allergic Rhinitis, Allergic Conjunctivitis and Food Allergies, Percentage of Patients who had allergic rhinitis, allergic conjunctivitis and food allergies at the end of the 36 month double blind study.

Note: The results at six years are not reported due to early termination of the study., 6 years (36 month Double-Blind Phase)|Corticosteroid and Pimecrolimus Drug Use, Corticosteroid and pimecrolimus study medication days of exposure during the 36 month double-blind phase.

Note: Although the double-blind phase was designed to be 36 months (3 years) in length, the last double-blind visit for some patients occurred after 36 months., 48 months|Atopic Dermatitis (AD) Remission Time, Longest duration of atopic dermatitis (AD) remission during the 36 month double-blind treatment phase. A remission day was defined as a diary day with a positive response (""yes"") to the question ""No or almost no eczema?"" and a response of no treatment except emollients to the question ""Medication used""., 36 month Double-Blind Phase|Patient/Caregiver Quality of Life, Change from Baseline in the total Parents' Index of Quality of Life-Atopic Dermatitis (PIQoL-AD) score in the double-blind phase. PIQoL-AD Score = (sum of valid items/number of valid items) \* 28. Scores range from a minimum value of 0 to a maximum value of 28 with a high total overall score indicating poor quality of life., From Baseline to Visit 5 , 6, 8, 10, 12, and 14",,Novartis Pharmaceuticals,,ALL,CHILD,PHASE4,1091,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CASM981CUS09,2003-10,2008-01,2008-11,2005-07-28,2010-12-08,2011-03-23,"Alabama Allergy and Asthma Center, Birmingham, Alabama, 35209, United States|Northwest Arkansas Pediatric Clinic, P.A., Fayetteville, Arkansas, 72703, United States|The Children's Clinic of Jonesboro, Jonesboro, Arkansas, 72401, United States|Southern California Research, Mission Viejo, California, 92691, United States|Children's Hospital of Orange County, Orange, California, 92868, United States|Stanford Dermatology Clinic and Clinical Trials Dept, Redwood City, California, 94063, United States|Capital Allergy Respiratory Disease Center, Sacramento, California, 95819, United States|Children's Hospital San Diego, San Diego, California, 92123, United States|Allergy and Asthma Medical Group of Diablo Valley, Inc./ Clinical Research Division, Walnut Creek, California, 94598, United States|National Jewish Medical and Research Center, Denver, Colorado, 80206, United States|Dermatology Associates and Research, Coral Gables, Florida, 33134, United States|Emerald Coast Clinical Research, Pensacola, Florida, 32503, United States|Children's Memorial Hospital, Chicago, Illinois, 60614, United States|Indiana University Outpatient Clinical Research, Indianapolis, Indiana, 46202, United States|Central Kentucky Research Associates, Lexington, Kentucky, 40509, United States|Dermatology Specialists, Louisville, Kentucky, 40202, United States|Rx R & D, Metarie, Louisiana, 70002, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States|Children's Hospital - Boston, Boston, Massachusetts, 02115, United States|Dermatology, PLLC, Ann Arbor, Michigan, 48103, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Central Dermatology, St Louis, Missouri, 63117, United States|Skin Specialists, P.C., Omaha, Nebraska, 68144, United States|Dartmouth-Hitchcock Medical Center/Dermatology Section, Lebanon, New Hampshire, 03756, United States|Children's Medical Group, Hopewell Junction, New York, 12533, United States|Dermatology Associates of St. Luke's - Roosevelt, New York, New York, 10025, United States|Calcagno Research and Development, Gresham, Oregon, 97030, United States|Oregon Health Science University - Dermatology Dept., Portland, Oregon, 97201, United States|The Childrens' Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|Tennessee Clinical Research Center, Nashville, Tennessee, 37215, United States|Texas Children's Hospital, BCM, Houston, Texas, 77030, United States|Alpine Medical Group, LLC, Salt Lake City, Utah, 84102, United States|Granger Medical Clinic, West Valley City, Utah, 84120, United States|Virginia Clinical Research, Norfolk, Virginia, 23507, United States|Asthma Inc, Seattle, Washington, 98105, United States",
